Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms
November 1, 2018 4:58 PM EDTCorcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67.41 million.
GUIDANCE:
Reaffirmed 2018 revenue guidance of $250-270 million
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
... More